Rolf Arno Stahel
#140,515
Most Influential Person Now
Rolf Arno Stahel's AcademicInfluence.com Rankings
Rolf Arno Stahelmedical Degrees
Medical
#2532
World Rank
#2960
Historical Rank
Oncology
#156
World Rank
#162
Historical Rank
Rolf Arno Stahelphilosophy Degrees
Philosophy
#7317
World Rank
#10511
Historical Rank
Logic
#4379
World Rank
#5662
Historical Rank
Download Badge
Medical Philosophy
Why Is Rolf Arno Stahel Influential?
(Suggest an Edit or Addition)Rolf Arno Stahel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. (2006) (1859)
- DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. (2006) (1388)
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. (2011) (605)
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma (2009) (603)
- Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. (2003) (401)
- 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. (2014) (362)
- CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. (1997) (326)
- Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. (2007) (313)
- 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. (2015) (292)
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop (2010) (289)
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (2015) (269)
- Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. (2004) (267)
- Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation (2003) (265)
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (262)
- CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. (1998) (246)
- Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. (2004) (244)
- Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. (2010) (233)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (231)
- Circulating DNA: a new diagnostic gold mine? (2002) (230)
- Staging and prognostic factors in small cell lung cancer: a consensus report (1989) (227)
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. (2014) (223)
- Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. (1997) (219)
- High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. (1999) (215)
- Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. (2005) (213)
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (209)
- Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. (2001) (205)
- Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program (2008) (196)
- Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). (2005) (191)
- Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study (2006) (185)
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. (2017) (172)
- Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. (2014) (168)
- A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. (2000) (164)
- Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. (2015) (159)
- Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. (2001) (151)
- Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. (2017) (148)
- Functional inactivation of NF2/merlin in human mesothelioma. (2009) (145)
- Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. (1998) (142)
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells (2013) (137)
- Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. (1985) (135)
- Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. (1989) (134)
- Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. (2011) (131)
- Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin‐6 production as a common feature (1992) (129)
- A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. (2003) (127)
- A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. (2019) (125)
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers (2018) (124)
- Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. (2010) (120)
- Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. (2005) (118)
- The MARS feasibility trial: conclusions not supported by data. (2011) (114)
- Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. (1997) (113)
- CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. (1992) (112)
- Biology of lung cancer. (1994) (112)
- Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. (2007) (111)
- Third international workshop on lung tumor and differentiation antigens: Overview of the results of the central data analysis (1994) (110)
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
- Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin (2012) (107)
- Induction of apoptosis in lung‐cancer cells following bcl‐xL anti‐sense treatment (2000) (105)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. (2021) (104)
- Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation (2005) (104)
- Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. (2009) (104)
- Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. (2019) (102)
- Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
- Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. (1994) (99)
- Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. (2004) (99)
- Chromosome changes in malignant mesothelioma. (1986) (96)
- Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. (2009) (94)
- PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. (2018) (94)
- Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? (2011) (93)
- Origin and prognostic value of circulating KRAS mutations in lung cancer patients. (2007) (93)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). (2005) (91)
- Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. (2002) (86)
- Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program (2007) (83)
- Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). (2019) (80)
- ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. (2012) (80)
- The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. (2006) (78)
- GAS5 long non-coding RNA in malignant pleural mesothelioma (2014) (77)
- Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. (2012) (76)
- PTEN expression is a strong predictor of survival in mesothelioma patients. (2008) (76)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
- Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. (2010) (75)
- Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. (1999) (73)
- Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin (2007) (71)
- Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl‐2 and Bcl‐xL antisense treatment (2003) (70)
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (70)
- Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. (2006) (70)
- Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide (2002) (70)
- bcl‐xl antisense treatment induces apoptosis in breast carcinoma cells (2000) (69)
- Antisense oligonucleotides for cancer therapy-an overview. (2003) (68)
- Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
- Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
- Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. (1990) (65)
- Role of Hedgehog Signaling in Malignant Pleural Mesothelioma (2012) (65)
- Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. (2011) (65)
- The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. (2004) (62)
- Recommendations for a Global Core Curriculum in Medical Oncology. (2004) (61)
- Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1) (2012) (61)
- Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. (2001) (60)
- Hippo/YAP pathway for targeted therapy. (2014) (59)
- 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. (2011) (58)
- The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). (2014) (58)
- A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma (2006) (57)
- Heterogeneity in cancer guidelines: should we eradicate or tolerate? (2008) (56)
- Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. (2011) (56)
- Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process. (1985) (53)
- Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. (1996) (52)
- Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. (2005) (52)
- A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience (2015) (51)
- Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. (1993) (50)
- ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. (1990) (50)
- Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring (2013) (49)
- Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. (1991) (49)
- Allelic loss on the short arm of chromosome 11 in non‐small‐cell lung cancer (1991) (48)
- A Novel BRCA1‐Associated Protein‐1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1‐Mediated DNA Repair (2017) (47)
- A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial (2019) (47)
- Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small‐cell carcinoma and squamous‐cell carcinomas (1985) (46)
- TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. (2008) (46)
- p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. (2006) (46)
- Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. (2006) (44)
- Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors (2015) (44)
- Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. (1995) (44)
- Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. (2008) (43)
- Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. (1997) (43)
- Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. (2004) (43)
- Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). (2020) (42)
- Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. (2004) (42)
- Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. (2017) (42)
- Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing (2014) (41)
- VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study (2022) (40)
- Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma (1988) (40)
- Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). (2014) (39)
- Successful publishing: how to get your paper accepted. (2009) (39)
- Swiss primary care physicians' knowledge, attitudes and perception towards genetic testing for hereditary breast cancer (2004) (39)
- Oncology for medical students: a European School of Oncology contribution to undergraduate cancer education. (2007) (38)
- Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. (2016) (38)
- Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. (1994) (38)
- Pleural mesothelioma side populations have a precursor phenotype. (2011) (38)
- Undergraduate training in oncology: an ESO continuing challenge for medical students. (2012) (37)
- VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. (2013) (37)
- Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients (2018) (37)
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. (2022) (37)
- Antibodies to the protein core of the small cell lung cancer workshop antigen cluster‐w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine‐alanine‐proline (1993) (36)
- Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. (2006) (36)
- Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. (1989) (36)
- Persistent polyclonal B‐cell lymphocytosis is an expansion of functional IgD+CD27+ memory B cells (2001) (35)
- Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. (2007) (35)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). (2005) (35)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
- First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. (2011) (34)
- Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma (1991) (34)
- Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. (2012) (33)
- A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. (2019) (33)
- Searching for targets for the systemic therapy of mesothelioma. (2015) (33)
- Management and Costs of Treating Lung Cancer Patients in a University Hospital (2012) (33)
- Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. (2015) (33)
- An autocrine mitogenic activity produced by a pleural human mesothelioma cell line (1992) (33)
- Treatment and detection of ALK-rearranged NSCLC. (2013) (33)
- A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. (2004) (33)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). (2005) (32)
- Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. (1984) (32)
- Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group fo (1995) (31)
- Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). (2012) (31)
- Strategies for improving outcomes in NSCLC: a look to the future. (2013) (31)
- PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy (2014) (31)
- The small cell lung cancer antigen cluster-4 and the leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21. (1995) (30)
- Combination chemotherapy with mitomycin, vindesine, and cisplatin for non‐small cell lung cancer association of antitumor activity with initial tumor burden and treatment center (1990) (30)
- Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC). (2017) (30)
- Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters (2014) (30)
- Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project (2012) (30)
- Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma (2016) (29)
- Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung. (1986) (29)
- Novel approaches to the treatment of small-cell lung cancer (1999) (29)
- Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT. (2012) (29)
- Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (brain-2). (1992) (29)
- Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. (1990) (29)
- Multimodality strategies in malignant pleural mesothelioma. (2009) (29)
- Lung cancer in non-smokers (2013) (29)
- Weekly Paclitaxel and Carboplatin Combination Chemotherapy in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (2003) (29)
- Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. (2012) (28)
- Diagnosis, staging, and prognostic factors of small cell lung cancer. (1991) (28)
- Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. (1989) (27)
- CD74: a new prognostic factor for patients with malignant pleural mesothelioma (2014) (27)
- Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells (1996) (27)
- T‐cell derived cytokines co‐stimulate proliferation of CD40‐activated germinal centre as well as follicular lymphoma cells (1997) (27)
- Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen (2019) (27)
- Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. (2021) (27)
- A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial (2021) (27)
- Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). (1996) (27)
- Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells. (1996) (27)
- Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019) (26)
- A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. (2017) (26)
- Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines. (1992) (26)
- Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (26)
- Proteomic surfaceome analysis of mesothelioma. (2012) (26)
- Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. (2008) (26)
- Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial. (2020) (26)
- Action of a cd24‐specific deglycosylated ricin‐a‐chain immunotoxin in conventional and novel models of small‐cell‐lung‐cancer xenograft (1993) (25)
- Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives (2013) (25)
- Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations (2003) (24)
- Characterization of an epithelial and a tumor-associated human small cell lung carcinoma glycoprotein antigen. (1987) (24)
- Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma (2015) (24)
- Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. (1992) (24)
- Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project (2018) (24)
- Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
- Monoclonal anti‐idiotypic antibody mimicking a tumor‐associated sialoglycoprotein antigen induces humoral immune response against human small‐cell lung carcinoma (1989) (23)
- Determinants of outcome of solitary fibrous tumors of the pleura: an observational cohort study (2014) (23)
- A standardised , generic , validated approach to stratify the magnitude of clinical bene fi t that can be anticipated from anti-cancer therapies : the European Society for Medical Oncology Magnitude of Clinical Bene fi t Scale ( ESMO-MCBS ) (2015) (22)
- Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. (2018) (22)
- CD 24 , a Mucin-Type Glycoprotein , Is a Ligand for P-Selectin on Human Tumor Cells (1997) (22)
- Early versus late alternating chemotherapy in small-cell lung cancer (1995) (22)
- Differential Effects of Lovastatin on Cisplatin Responses in Normal Human Mesothelial Cells versus Cancer Cells: Implication for Therapy (2012) (22)
- A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial (2020) (22)
- Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (22)
- ΔNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells (2005) (22)
- Tumor-associated membrane sialoglycoprotein on human small cell lung carcinoma identified by the IgG2a monoclonal antibody SWA20. (1988) (22)
- ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. (2005) (22)
- Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data. (2022) (22)
- Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. (1990) (21)
- Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients. (2017) (21)
- Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. (2012) (21)
- Morphologic analysis of human lymphokine‐activated killer (LAK) cells (1990) (21)
- Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody. (1991) (21)
- The 5′‐flanking region of human CD24 gene has cell‐type‐specific promoter activity in small‐cell lung cancer (1998) (20)
- Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project. (2021) (20)
- Tumor‐antigen‐specific humoral immune response of animals to anti‐idiotypic antibodies and comparative serological analysis of patients with small‐cell lung carcinoma (1992) (20)
- Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. (1997) (20)
- Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes. (1993) (20)
- Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. (2011) (20)
- Adenocarcinoma, a molecular perspective. (2007) (20)
- Systemic fungal infections in haematological malignancies: A growing problem (1982) (20)
- LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial (2020) (19)
- Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. (1985) (19)
- Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). (2013) (19)
- Aggressive lymphoma: improving treatment outcome with rituximab (2002) (19)
- Immune Reactivity Against a Novel HLA-A3-Restricted Influenza Virus Peptide Identified by Predictive Algorithms and Interferon-&ggr; Quantitative PCR (2003) (19)
- ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. (2005) (19)
- Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. (2010) (19)
- ESMO clinical recommendations: a practical guide for medical oncologists. (2007) (18)
- A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells (2019) (18)
- Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. (2015) (18)
- Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma (2016) (18)
- Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. (1995) (18)
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). (2019) (17)
- A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial. (2020) (17)
- Pretreatment minimal staging for non-small cell lung cancers: a consensus report (1991) (17)
- Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. (1994) (17)
- Selective cytotoxicity of murine monoclonal antibody LAM2 against human small‐cell carcinoma in the presence of human complement: Possible use for in vitro elimination of tumor cells from bone marrow (1985) (17)
- A comparison of 67Cu‐ and 131I‐labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small‐cell lung cancer (1994) (17)
- Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer. (1992) (17)
- Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. (2007) (16)
- Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim (2010) (16)
- Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression (2018) (16)
- Primary non-small cell lung cancer response upon treatment with denosumab. (2013) (16)
- Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer. (1994) (16)
- The masterclass of the european school of oncology: the 'key educational event' of the school. (2010) (16)
- In vitro effect of suramin on lung tumour cells. (1993) (16)
- Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide. (2002) (16)
- Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. (2005) (16)
- Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. (2018) (16)
- Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (15)
- False-Positive Human Serum Chorionic Gonadotropin in a Patient with a History of Germ Cell Cancer (2004) (15)
- Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer. (1991) (15)
- Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. (2016) (15)
- Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01) (2019) (14)
- VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data (2021) (14)
- Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial. (2019) (14)
- Antigens of lung cancer: results of the Third International Workshop on Lung Tumor and Differentiation Antigens. (1994) (14)
- Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. (2015) (14)
- Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells (2016) (14)
- Organizing cancer genetics programs: the Swiss model. (2000) (14)
- Expression of the small cell carcinoma antigens of cluster-5 and cluster-5A in primary lung tumours. (1989) (13)
- ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). (2005) (13)
- Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress (2014) (13)
- Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition (2019) (13)
- Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines. (2011) (13)
- Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach? (2009) (13)
- ME1-antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies. (1994) (13)
- Recommendations for a global core curriculum in medical oncology. (2004) (13)
- Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297 (2011) (13)
- Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. (2019) (13)
- Malignant pleural mesothelioma: a new standard of care. (2006) (13)
- Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients (2017) (13)
- High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas. (1995) (13)
- EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). (2016) (13)
- LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial (2021) (12)
- Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. (1985) (12)
- Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
- Prognostic and diagnostic usefulness of serum markers in lung cancer. (1987) (11)
- The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies. (1994) (11)
- Ectopic expression of human topoisomerase IIα fragments and etoposide resistance in mammalian cells (2000) (11)
- Potent anti‐tumor effects of an anti‐CD24 ricin A‐chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice (1996) (11)
- Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial (2017) (11)
- Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis (2015) (11)
- Surgical resection of residual tumor after chemotherapy in non-seminomatous testicular cancer. (1982) (11)
- Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors. (2004) (11)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. (2005) (10)
- Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma. (2013) (10)
- miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery (2019) (10)
- 1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (10)
- Successes and limitations of targeted cancer therapy (2014) (10)
- Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma (2017) (10)
- Selection and immunomagnetic purging of peripheral blood CD34+ cells for autologous transplantation in B-cell non-Hodgkin's lymphomas. (1998) (10)
- Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients†. (2017) (10)
- STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT (2016) (10)
- Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors. (1992) (9)
- Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma (MPM): A multicenter phase II trial of the SAKK. (2004) (9)
- Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer. (1993) (9)
- Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors. (2002) (9)
- Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial (2019) (9)
- LBA37_PRNEOADJUVANT CHEMOTHERAPY AND EXTRAPLEURAL PNEUMONECTOMY (EPP) OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) WITH OR WITHOUT HEMITHORACIC RADIOTHERAPY: FINAL RESULTS OF THE RANDOMIZED MULTICENTER PHASE II TRIAL SAKK17/04 (2014) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- C3-07: Preoperative chemoradiotherapy followed by surgery for stage IIIB non-small cell lung cancer (NSCLC). A multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) (2007) (9)
- Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule (1992) (9)
- Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. (2009) (9)
- Risk-Adapted Chemotherapy of Germ Cell Tumors with Carboplatin, Etoposide and Bleomycin for Low-Risk and Cisplatin, Etoposide and Ifosfamide for High-Risk Patients (2000) (9)
- A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer (1997) (9)
- ESMO clinical recommendations: using the easier and faster approach to oncology guidelines. (2009) (8)
- A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib. (2015) (8)
- Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. (2015) (8)
- D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC (2007) (8)
- Anti‐tumor activity of a blocked ricin immunotoxin with specificity against the cluster‐5A antigen associated with human small‐cell lung cancer (1993) (8)
- Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer. (2008) (8)
- Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation (2010) (8)
- A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. (2018) (8)
- Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines. (1991) (8)
- GAS 5 long non-coding RNA in malignant pleural mesothelioma (2017) (8)
- EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. (2022) (8)
- Radial segmentation of nuclei (Rieder cells): a morphological marker of T-cell neoplasms? (1983) (7)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma. (2005) (7)
- ESMO minimum clinical recommendations--the beginning of a process. (2001) (7)
- HIV-testing and Newly-diagnosed Malignant Lymphomas. The SAKK 96/90 Registration Study (2003) (7)
- ESMO Clinical Practice Guidelines: development, implementation and dissemination. (2010) (7)
- Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. (2019) (7)
- Imaging and therapy of small cell carcinoma xenografts using 131I-labeled monoclonal antibody SWA11. (1990) (7)
- Consensus Conference on Lung Cancer : early-stage non-small-cell lung cancer consensus on diagnosis , treatment and follow-up (2014) (7)
- Non-small cell lung cancer: second-line and beyond. (2006) (7)
- Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer (2005) (7)
- Evidence-based oncology in cancer treatment reviews. (2003) (7)
- Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. (2019) (7)
- Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. (2020) (7)
- Chapter 30 Characterisation of small cell carcinoma surface membrane antigens by indirect immunofluorescence. Solid phase radioimmunoassay and immunoblotting (1988) (6)
- Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience (2020) (6)
- Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. (2001) (6)
- A Comprehensive Analysis of Markers for Neuroendocrine Tumors of the Lungs Demonstrates Estrogen Receptor Beta to be a Prognostic Markers in SCLC Male Patients (2014) (6)
- Radiation studies on B cell differentiation marker CD24/SCLC Cluster-4 antigen expressing and non-expressing lung cancer cell lines and mouse fibroblasts. (1995) (6)
- Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin's disease. (1997) (6)
- A prospective study of risk‐adapted therapy for large cell non‐Hodgkin's lymphoma with VACOP‐B followed by high‐dose CBV and autologous progenitor cell transplantation for high‐risk patients in remission (1999) (6)
- Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy (2019) (6)
- Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort (2018) (6)
- Real-Time Polymerase Chain Reaction Monitoring of Epithelial Cell Adhesion Molecule-Induced T-Cell Stimulation in Patients With Lung Cancer and Healthy Individuals Using LightCycler Technology (2002) (6)
- Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib. (2013) (6)
- ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test (2019) (6)
- Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. (2018) (6)
- Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. (2017) (6)
- The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells. (1999) (5)
- Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant pleural mesothelioma (MPM): Results of the International Expanded Access Program (EAP) (2007) (5)
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells (2013) (5)
- Malignant pleural mesothelioma. (2009) (5)
- Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. (2013) (5)
- [Systemic mycoses in hematologic neoplasms]. (1983) (5)
- Neoadjuvant chemotherapy in malignant pleural mesothelioma. (2005) (5)
- Underweight and weight loss are predictors of poor outcome in patients with brain metastasis (2019) (5)
- [Diffuse thymus hyperplasia following chemotherapy for nodular sclerosing Hodgkin lymphoma]. (1994) (5)
- Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small cell lung cancer (NSCLC): Preliminary results. A study of the Swiss Group for Clinical Cancer Research (SAKK) (2005) (5)
- Diagnostic value of 18 F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site (2018) (5)
- Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals. (1991) (4)
- Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapy (2018) (4)
- Response evaluation by CT and FDG-PET/CT in malignant pleural mesothelioma (MPM) (2008) (4)
- Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant pleural mesothelioma. (2005) (4)
- VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial (2021) (4)
- Syndrome of inappropriate ADH secretion secondary to vinblastine (2004) (4)
- Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. (2011) (4)
- C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP) (2007) (4)
- Monoclonal antibodies defining the cluster-5A small cell lung carcinoma antigen. (1991) (4)
- PD-068 An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel (2005) (4)
- A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bclxL bclxL bclxL Expression Efficiently Induces Apoptosis in Tumor Cells 1 (2000) (4)
- Autoantibodies in neurological paraneoplastic diseases. (1994) (4)
- O-032 Neoadjuvant therapy with docetaxel and cisplatin in patients with non-small cell lung cancer (NSCLC), stage IIIA, pN2: A large phase II study with 59 months of follow-up (2005) (4)
- ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines. (2012) (4)
- Intracavitary Cisplatin-Fibrin Chemotherapy After Resection For Malignant Pleural Mesothelioma Patients (Influence-Meso) - Preliminary Results (2013) (4)
- Chapter 6 Reactivity of SCLC associated monoclonals SWA4, SWA20 & SWA23 in formalin paraffin sections (1988) (4)
- ESMO Minimum Clinical Recommendations: assuring common standards of care. (2005) (4)
- The ESMO guideline strategy: an identity statement and reflections on improvement. (2015) (4)
- [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich]. (2000) (4)
- Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma (2020) (3)
- Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05. (2011) (3)
- [Idiopathic splenomegaly: the preliminary stage of a malignant lymphoma? Report on 2 cases]. (1982) (3)
- Current models, challenges and best practices for work conducted between European academic cooperative groups and industry (2020) (3)
- 9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression – a multicenter phase II trial of SAKK (2009) (3)
- Morphology, surface antigens, staging, and prognostic factors of small cell lung cancer (1992) (3)
- Monoclonal antibodies in lung cancer. (1989) (3)
- Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule. (2004) (3)
- 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091 (2022) (3)
- 57 Pemetrexed vs docetaxel: a phase III study in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy (2003) (3)
- Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer. (1994) (3)
- Erratum: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients (Annals of Oncology) (2002) vol. 13 (1853-1861)) (2003) (3)
- O-144 Result of a phase II study conducted in elderly patients with unresectable localised or metastatic non-small-cell-lung cancer (NSCLC) with oral vinorelbine given as a weekly monotherapy (2003) (3)
- Reduction of systemic fungal infections in patients with hematological malignancies, neutropenia, and prolonged fever by early amphotericin B therapy (1988) (3)
- Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer. (2012) (3)
- Neoadjuvant therapy with Docetaxel (TAX) and Cisplatin (CIS) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA, N2 is highly active with few toxicities (2000) (3)
- EMT in NSCLC and malignant pleural mesothelioma (2010) (3)
- Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. (2021) (3)
- Neoadjuvant chemotherapy and extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM) (2001) (3)
- 143TiPSPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS (2015) (2)
- External Quality Assessment for ALK Immunohistochemistry Testing in Lung Adenocarcinoma Within the European Thoracic Oncology Platform Lungscape Project (2012) (2)
- The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. (2013) (2)
- Circulating DNA : a new diagnostic gold mine ? q (2002) (2)
- [Systemic therapy of metastatic malignant melanoma]. (1988) (2)
- Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). (1995) (2)
- O-200 Neoadjuvant chemotherapy followed by pleuropneumonectomy for pleural mesothelioma: a multicenter phase II trial of the SAKK (2003) (2)
- Non-small cell lung cancer, early stage (2012) (2)
- Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project (2015) (2)
- A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial (2017) (2)
- [Decrease in systemic fungal infections in hematological neoplasms with empirical use of amphotericin B therapy]. (1989) (2)
- Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. (2022) (2)
- Biologicals in the therapy of lung cancer (1991) (2)
- Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis (2022) (2)
- 32 Single-agent Gemzar® (Gemcitabine, GEM) versus cisplatin plus etoposide (CE): A randomized phase II study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (1997) (2)
- Small cell carcinoma antigens (1988) (2)
- 1417TiP Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial (2020) (1)
- Cell surface antigens as therapeutic targets (1997) (1)
- Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma (2022) (1)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. (2005) (1)
- Third International IASLC Workshop on Lung Tumor and Differentiation Antigens, University Hospital Zurich, Switzerland, September 8-11, 1993 (1994) (1)
- Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring (2013) (1)
- Action of cytosine arabinoside on human tumor cells isolated from malignant effusions: in vitro phosphorylation and inhibition of DNA synthesis. (1979) (1)
- Biological basis of combined therapy (1994) (1)
- Membrane antigens of human bronchial epithelial cells identified by monoclonal antibodies (1988) (1)
- Pathological complete response of a patient with ALK-translocated adenocarcinoma of the lung upon treatment with crizotinib followed by alectinib (2015) (1)
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. (2005) (1)
- Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatment (2022) (1)
- Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. (2017) (1)
- Lung Cancer Therapy Annual 7 (2012) (1)
- Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease. A phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) (2007) (1)
- Cancer treatment reviews welcomes submission of the Cochrane Reviews. (2006) (1)
- Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort (2016) (1)
- Results of a Pilot External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer Managed by EMQN, ESMO, ESP, and ETOP (2011) (1)
- Incidence of non-metastatic extrathoracic lesions detected by whole-body FDG PET-CT imaging in patients with non-small-cell lung cancer. (2004) (1)
- 21P Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen (2018) (1)
- Cytotoxicity and therapeutic potential of immunotoxins recognizing different antigens of small cell lung cancer (1991) (1)
- Response to Induction Therapy Confers a Significant Survival Benefit in Patients with Resected T4 Non-Small Cell Lung Cancer (2018) (1)
- Interleukin-2 as single agent (1993) (1)
- P-418 Incidence and management of surgical complications after induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma (2005) (1)
- Antisense oligonucleotides targeting the expression of anti-apoptotic proteins in lung cancer cells (2000) (1)
- P-592 Neoadjuvant chemo- and radiotherapy in stage IIIA (N2) non-small cell lung cancer (NSCLC). Rationale for a radomized trial by the swiss group for clinical cancer research (SAKK) (2003) (1)
- Clinical recommendations for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop. (2010) (1)
- Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539-545). (2003) (1)
- [Spontaneous radial segmentation of cell nuclei: morphologic marker of T-cell neoplasms?]. (1983) (1)
- Biomarker testing in non-small cell lung cancer: to move forward with quality (2012) (1)
- 3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project (2015) (1)
- A clinical-based risk score for decision making for surgery after induction chemotherapy in malignant pleural mesothelioma patients. (2013) (1)
- Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. (2011) (1)
- [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells]. (1988) (1)
- Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al. (2014) (1)
- Sarcomatoid differentiation during progression of malignant pleural mesothelioma (2015) (1)
- [High-dosage chemo-radiotherapy with autologous bone marrow transfusion in malignant lymphoma: indications and personal experience]. (1989) (1)
- 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC (2011) (1)
- Educational book of the 33rd ESMO Congress Stockholm, Sweden 12-16 September 2008. Introduction. (2008) (1)
- The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis (2020) (1)
- Antisense oligonucleotides for cancer therapy * /an (2003) (1)
- MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09) (2017) (1)
- Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1) (2012) (1)
- Surgery and multimodality treatment for malignant pleural mesothelioma (2009) (1)
- P-606 Neoadjuvant chemo- and radiotherapy for stage IIIB non-small cell lung cancer (NSCLC). A prospective multicenter trial by the Swiss group for clinical cancer research (SAKK) (2003) (1)
- [5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion in malignant lymphoma with a high risk of recurrence]. (1993) (1)
- 175 Induction chemotherapy with cisplatine/gemcitabine compared to cisplatin/pemetrexed followed by extrapleural pneumonectomy for malignant pleural mesothelioma (2006) (1)
- Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (1)
- ESMO Guidelines Committee. (2018) (0)
- Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers. (2014) (0)
- WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER (2017) (0)
- Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. (2022) (0)
- The ESMO CME Program: How Practicing Oncologists Can Maintain their Knowledge in the E-Era? Certification and Recertification Opportunities (2009) (0)
- Original Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin's disease (2005) (0)
- F-052EVALUATION OF TUMOUR IMAGING TECHNIQUES FOR MALIGNANT PLEURAL MESOTHELIOMA ORTHOTOPIC RAT MODEL (2014) (0)
- 1063 New directions in the treatment of mesothelioma (2003) (0)
- Asbestos-induced tissue regeneration and malignant pleural mesothelioma: Insights from developmental studies (2011) (0)
- 1IN MILESTONES IN THE MANAGEMENT OF LUNG CANCER (2009) (0)
- ntrapleural topical application of cisplatin with the urgical carrier Vivostat increases the local drug oncentration in an immune-competent rat model with alignant pleuromesothelioma (2009) (0)
- 155OCHEMOTHERAPY OF MALIGNANT PLEURAL MESOTHELIOMA DOES NOT PRECLUDE USE OF CHECK-POINT BLOCKADE (2015) (0)
- SL1ESMO International: deep roots and enlightened initiatives between the European and Japanese Oncology Community (2015) (0)
- 1 ROLE OF HEDGEHOG SIGNALING IN MALIGNANT PLEURAL MESOTHELIOMA (2012) (0)
- F-037RELAPSE PATTERN AFTER MULTIMODALITY TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA (2015) (0)
- Introduction (0)
- Biology of lung tumours: targeting bcl-xL and EGP-2 (1999) (0)
- Front & Back Matter (2015) (0)
- Overview of the IASLC Mesothelioma workshop 2004 (2005) (0)
- Selective Cytotoxicity of the SM 1 Monoclonal Antibody towards Small Cell Carcinoma of the Lung 1 (2006) (0)
- Mediast inal Lymph Node Clearance Af ter (2009) (0)
- P55. In situ molecular assessment of CD8+ T cell reactivity in NSCLC (2006) (0)
- Front & Back Matter (2015) (0)
- Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al. (2014) (0)
- 405P Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019 (2022) (0)
- 214O Multiplexed proteomics biomarkers for malignant pleural mesothelioma detection in blood (2018) (0)
- Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO) (2004) (0)
- P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01) (2021) (0)
- IHC examples for nestin and periostin. (2015) (0)
- Change of nestin and periostin expression after neo-adjuvant chemotherapy. (2015) (0)
- O-076 Staging of malignant pleural mesotheliona with integratedPET/CT and its histopathological and surgical correlation (2005) (0)
- Vol. 23, Supplement 3, April 2000 (2000) (0)
- Molecular strategies for therapy of small cell lung cancer (1998) (0)
- Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (2022) (0)
- Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (2022) (0)
- Molecular intervention in small cell lung cancer (1997) (0)
- [Recent advances in malignant pleural mesothelioma management]. (2006) (0)
- [Current status and perspectives in the treatment of tumor with biological substances]. (1988) (0)
- Front & Back Matter (2014) (0)
- 815 Elderly patients (pts) with unresectable localised or metastatic non-small-cell-lung-cancer (NSCLC): results of a phase II study with oral navelbineâ (nvb) given as a weekly monotherapy and first line treatment (2003) (0)
- A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial. (2022) (0)
- EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW (2019) (0)
- Front & Back Matter (2014) (0)
- Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug. (2020) (0)
- Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin (2012) (0)
- P-484 CCND1/Cyclin D1 A870G gene polymorphism is associated with non-small cell lung cancer (NSCLC) risk, and affects prognosis and response to chemotherapy (2005) (0)
- MA 06.06 Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort (2017) (0)
- Abstract 5333: Novel Ab treatment tool for CRC (2010) (0)
- ESO Society Symposium: Celebrating 30 years of ESO and 50 issues of Cancer World. Cancer 2020: The road to personalized cancer care (2012) (0)
- 152PD A 10 YEAR FOLLOW-UP OF A SINGLE CENTRE EXPERIENCE WITH INDUCTION CHEMOTHERAPY FOLLOWED BY EXTRAPLEURAL PNEUMONECTOMY FOR MALIGNANT PLEURAL MESOTHELIOMA (2009) (0)
- P1.09-001 Multiplexed Biomarker Strategies Based on Targeted Proteomics for Detection of Malignant Pleural Mesothelioma in Blood (2017) (0)
- Contents Vol. 26, 2003 (2003) (0)
- A New Prognostic Score for Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma – An Update (2016) (0)
- Rolf Stahel & Dirk Arnold: Trends in Lung Cancer Treatment and Key Roles of Comprehensive Cancer Centers (2018) (0)
- T1151 Chimeric Recombinant Anti-CD24 Antibody: A Novel Tool for Colorectal Cancer Therapy (2010) (0)
- Cancer Therapy : Preclinical Role of Hedgehog Signaling in Malignant Pleural Mesothelioma (2012) (0)
- Comment on: A pilot trial of g3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. By Reeve J G et al (2003) (0)
- NF 2 is a “ gatekeeper ” during tissue repair normal tissue repair cell-cell contact stimulation of repair in NF 2 signaling deficient cell (2016) (0)
- non-small cell lung cancer, early stage 1179O THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT: A WAY TO BRIDGE NON-SMALL CELL LUNG CANCER MOLECULAR CHARACTERISTICS AND CLINICAL DATA (2012) (0)
- Welcome to the 3rd European Lung Cancer Conference (2012) (0)
- Proteomic Surfaceome Analysis of Mesothelioma 1 2 (2017) (0)
- [Current therapy concepts in early and intermediate stages of Hodgkin diseases in adults]. (1995) (0)
- Components of homologous recombination and translesion synthesis (TLS) in pemetrexed/cisplatin-treated non-small-cell lung cancer (NSCLC) patients (p). (2013) (0)
- The Lungscape Project. (2012) (0)
- Is distinct EGFR mutation status proof of second simultaneous primary non-small cell lung cancer? (2012) (0)
- Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib (2014) (0)
- 25PD CIRCULATING MICRO-RNA PROFILING IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON SMALL-CELL LUNG CANCER RECEIVING BEVACIZUMAB/ERLOTINIB FIRST-LINE TREATMENT FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY AT DISEASE PROGRESSION (SAKK 19/05) (2013) (0)
- Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (2022) (0)
- Cytotoxic activity of doxorubicin and ETA 42 immunoconjugates against drug resistant small cell lung cancer cell lines in vitro: 13 (1994) (0)
- Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (2022) (0)
- Association of markers with histology in cohort 1. (2015) (0)
- 393MO Evaluating medical oncology outcomes (EMOO) in Asia study: Molecular testing, treatment patterns and outcome of patients with stage IV non-squamous non-small cell lung cancer (2022) (0)
- 1630PDAssociation of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort (2017) (0)
- Use of monoclonal antibodies to purge bone marrows in the treatment of small cell lung cancer (1988) (0)
- A6 Decision-making in the treatment of non-small cell lung cancer (2010) (0)
- Monoclonal antibody to lung cancer and cell surface antigen (1989) (0)
- Identification of cancer stem cells in malignant pleural mesothelioma (2019) (0)
- Front & Back Matter (2014) (0)
- 173 Integrating chemotherapy into multi-modality treatment (2006) (0)
- Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort (2019) (0)
- Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death. (2020) (0)
- Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP) (2007) (0)
- 736 Molecular concepts (2003) (0)
- Personalized Therapy in Lung Cancer: The Promise for the Future (2012) (0)
- P-409 Pharmacokinetic study after intrapleural topical application ofcisplatin for malignant pleuromesothelioma in immune competent rat model (2005) (0)
- FP05.02 An Early Detection and Prognostic Blood Biomarkers Signature for Malignant Pleural Mesothelioma Based on Targeted Proteomics (2021) (0)
- YI04.03 The Place of Immunotherapy in NSCLC Therapeutic Algorythm (2019) (0)
- P3.03-044 Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?: Topic: Mesothelioma Clinical (2017) (0)
- Front & Back Matter (2014) (0)
- Poseban članak Sadašnja i buduća uloga medikalnog onkologa u profesionalnom zbrinjavanju onkoloških pacijenata: stav Evropskog udruženja za medikalnu onkologiju (ESMO) (2014) (0)
- Dose, scheduling and optimum immunomodulatory dose (1993) (0)
- 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis (2022) (0)
- Evaluating medical oncology outcomes: An Asian lung cancer study (2019) (0)
- 567 Antisense-mediated downregulation of BCL-2 and BCL-XL expression in lung cancer cell lines: Biologic implication and potential therapeutic benefit (1997) (0)
- ESMO Minimum Clinical Recommendations: assuring common standards of care. (2005) (0)
- 31PTargeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort (2017) (0)
- Kaplan-Meier curves. (2015) (0)
- Results of the Second Pilot External Quality Assurance Scheme for Somatic Egfr Mutation Testing in Non-Small-Cell Lung Cancer (NSCLC) (2012) (0)
- P-198STEREOTACTIC BODY RADIATION THERAPY AS SALVAGE THERAPY FOR OLIGOMETASTATIC PLEURAL MESOTHELIOMA AFTER CURATIVE INTENT MULTI-MODAL THERAPY (2017) (0)
- Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries (2022) (0)
- CMET-26. DIAGNOSTIC VALUE OF FDG-PET/CT FOR PATIENTS WITH BRAIN METASTASIS FROM UNKNOWN PRIMARY SITE (2017) (0)
- Intracavitary cisplatin fibrin application following resection of mesothelioma (2016) (0)
- P-436 Neoadjuvant chemotherapy followed by pleuropneumonectomy and radiotherapy for pleural mesothelioma: A multicenter phase II trial of the SAKK (2005) (0)
- Status of Topotecan in Small-Cell Lung Cancer (2000) (0)
- Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). (2010) (0)
- MLTI-09. UNDERWEIGHT AND WEIGHT LOSS ARE PREDICTORS OF POOR OUTCOME IN PATIENTS WITH BRAIN METASTASIS (2019) (0)
- Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort. (2022) (0)
- Influence of HAMA on tumor cell lysis capacity of sera of patients treated with murine antitumor MAB SDZ ABL 364 (1991) (0)
- Front & Back Matter (2014) (0)
- GAS5 long non-coding RNA in malignant pleural mesothelioma (2014) (0)
- Antisense strategies for induction of tumor cell apoptosis (2001) (0)
- A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib. (2015) (0)
- LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. (2021) (0)
- EJ-1TRANSLATIONAL RESEARCH IN LUNG CANCER: FROM THE PERSPECTIVE OF THE EUROPEAN THORACIC ONCOLOGY PLATFORM(ETOP) (2014) (0)
- 11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma (2022) (0)
- Prognostic factors in an open-label, nonrandomized study in chemonaive, malignant pleural mesothelioma (MPM) patients receiving pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) (2008) (0)
- P3.04-009: Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project (2015) (0)
- Quality of life (QoL) in SAKK 19/03: A multicenter phase II study of first-line gefitinib followed by chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Swiss Group for Clinical Cancer Research (SAKK). (2006) (0)
- The expanding role of systemic treatment in NSCLC (2006) (0)
- Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR) (2019) (0)
- MA06.03 Phosphorylated Ribosomal Protein S6, Correlation With Characteristics and Clinical Outcome in Patients With MPM: Results from ETOP Mesoscape (2021) (0)
- [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. (2010) (0)
- PD2-3-1: Prognostic significance and origin of plasma KRAS mutations in patients with non-small cell lung cancer (NSCLC) (2007) (0)
- 16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial (2023) (0)
- ETOP activity in the field of biomarkers and predictors (2012) (0)
- 97 Cisplatin-induced apoptosis in malignant pleural mesothelioma cells involves p53 but not p14ARF (2006) (0)
- Multiplexed targeted proteomics signature for serum diagnostic of malignant pleural mesothelioma (2017) (0)
- European School of Oncology First Euro-American Forum Treatment on Lung Cancer (2003) (0)
- Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials. (2018) (0)
- Effect of first-line treatment and CHFR and 14-3-3{sigma} methylation status on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in stage IV non-small-cell lung cancer (NSCLC) (2008) (0)
- Subject Index Vol. 26, 2003 (2003) (0)
- Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. (2022) (0)
- Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial (2016) (0)
- PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09) (2017) (0)
- Chemotherapy of Malignant Pleural Mesothelioma Induces Both Senescence and Apoptosis (2013) (0)
- Front & Back Matter (2014) (0)
- 191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study (2023) (0)
- A novel germline mutation of PDGFR- b might be associated with clinical of (2014) (0)
- P1.02-025 Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
- 10IN NEW TOOLS IN THE MOLECULAR DIAGNOSTIC OF LUNG CANCER (2011) (0)
- ESMO-CSCO - Building the clinical trials of the future (2012) (0)
- Monoclonal antibody me1 against mesothelial membrane antigen discriminates between malignant mesothelioma and adenocarcinoma of the lung (1987) (0)
- Molecular andbiological properties ofanabrin A chainimmunotoxin designed fortherapy ofhumansmall celllungcancer (1992) (0)
- Morphologic analysis of lymphokine activated killer lak cell mediated cytolysis (1988) (0)
- Front & Back Matter (2014) (0)
- 37IN EUROPEAN TREATMENT GUIDELINES: MESOTHELIOMA (2009) (0)
- 6571 POSTER Open-label study of pemetrexed (P) alone or in combination with a platinum in patients (pts) with peritoneal mesothelioma (PM): results from the international expanded access program (EAP) (2007) (0)
- Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience (2020) (0)
- 1199PDPREVALENCE AND CLINICAL OUTCOMES FOR PATIENTS WITH MET PROTEIN EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN EUROPE: RESULTS FROM THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT. (2014) (0)
- [5 and 10 years results of surgical treatment of lung metastases]. (1990) (0)
- Front & Back Matter (2014) (0)
- Monoclonal Antibody SEN ? Recognizes a New Epitope on the Neural Cell Adhesion Molecule Present on Small Cell Lung Cancer but Not on Lymphocytes 1 (2006) (0)
- EP-1414: Toxicity of concurrent stereotactic radiotherapy and targeted or immunotherapy: a systematic review (2017) (0)
- Author ' s response to reviews Title : Determinants of outcome of solitary fibrous tumors of the pleura : an observational cohort study Authors : (2014) (0)
- IBS06.01 Realtime Data from Europe ETOP / ESTS Database (2019) (0)
- Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply. (2016) (0)
- 1IN CLINICAL TRIALS AND TRANSLATIONAL RESEARCH IN EUROPE – THE ROLE OF ETOP (2011) (0)
- EP-1365 SBRT as salvage therapy for oligometastatic pleural mesothelioma after initial curative therapy (2019) (0)
- Intracavitary Cisplatin-Fibrin After Resection of Malignant Pleural Mesothelioma; JOURNAL OF THORACIC ONCOLOGY (2015) (0)
- 5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING (2011) (0)
- Antibodies in Diagnosis and Therapy (2019) (0)
- [Non-Hodgkin lymphoma: diagnosis and therapy]. (1988) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rolf Arno Stahel?
Rolf Arno Stahel is affiliated with the following schools:
